Congress Materials – American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2025)
2025 American Association of Neuromuscular & Electrodiagnostic Medicine | Oct 29 - Nov 1 | San Francisco, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Analysis of Long-Term Efficacy of Nipocalimab in Myasthenia Gravis: Open-Label Extension of the Vivacity-MG3 Trial
Nicholas J. Silvestri, Maria Ait-Tihyaty, Kavita Gandhi, Ibrahim Turkoz, Zia Choudhry, Wim Noel, Charlotte Gary, Sindhu Ramchandren
Composite Response To Nipocalimab Based On Both Myasthenia Gravis Activity Of Daily Living And Quantitative Myasthenia Gravis Scores In Patients With Generalized Myasthenia Gravis
Said R. Beydoun, Maria Ait-Tihyaty, Ibrahim Turkoz, Kavita Gandhi, Sindhu Ramchandren
Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab (EPIC): Study design and Rationale
Srikanth Muppidi, Andrea Corse, Heinz Wiendl, Ibrahim Turkoz, Ruben Faelens, Zia Choudhry, John J Sheehan, Maria Ait-Tihyaty, Nolan Campbell
Efficacy of Nipocalimab in Adult Patients with Moderate-to-severe Ocular Manifestations of Generalized Myasthenia Gravis in Phase 3 Vivacity-MG3 Study
Kristl G. Claeys, Kavita Gandhi, Maria Ait-Tihyaty, Ibrahim Turkoz, Sheryl Pease, Charlotte Gary, Zia Choudhry, Sindhu Ramchandren
Efficacy of Nipocalimab in Open-Label Extension in Patients Transitioned from Placebo: Results from Vivacity-MG3 Trial
Kristl G. Claeys, Maria Ait-Tihyaty, Kavita Gandhi, Ibrahim Turkoz, Zia Choudhry, Wim Noel, Charlotte Gary, Sindhu Ramchandren, Tuan Vu
Factors Associated with Myasthenia Gravis – Activities of Daily Living Score in a Real-World, United States Population Prescribed Standard of Care Therapy
Jacqueline Pesa, Louis Jackson, Alex Keenan, Nolan Campbell, Gregor Gibson, Hannah Connolly, Shiva Lauretta Birija, Beth Poirrette, Raghav Govindarajan
Impact of Generalized Myasthenia Gravis on Pregnancy Outcomes: Findings from a Healthcare Claims Database
Louis Jackson, Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak, Melanie Jacobson, Nolan Campbell, Béatrice Libchaber, Francesca Lee, Dominic Pilon, Zia Choudhry, Neelam Goyal
Insights Into Nipocalimab-Neonatal Fragment Crystallizable Receptor Structure (FcRn), Binding Affinity, and Inhibition of Immunoglobulin G Recycling: Comparison With Efgartigimod
Nilufer Seth, Rui Xu, Brian Stoveken, Matthew DuPrie, Samuel Sihapong, Traymon Beavers, Leona E. Ling, Maria Ait-Tihyaty, John J. Sheehan, Tuan Vu
Nipocalimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Diagnostic Adjudication of the First 110 Patients of the Phase 2/3 ARISE Study
Ken Gorson, Thomas Harbo, Jonathan Katz, Richard A. Lewis, Bob Murray, Phillippe Linscheid, Rachel Kolster, Lisa Ford
Patient and Caregiver Experiences of Symptom Instability and Unpredictability from a Myasthenia Gravis Patient Engagement Research Council: A Generative AI-Assisted Analysis
Nicholas Streicher, OluYemisi Falope, Bruce West, Victor Wang, Rebecca Genin, Louis Jackson, Zia Choudhry, Kavita M. Grover
Predictors of Composite Response in Myasthenia Gravis Based on Patient and Clinician-Reported Assessments—In Vivacity-MG3 Phase 3 Trial
Elena Cortés Vicente, Ibrahim Turkoz, Maria Ait-Tihyaty, Kavita Gandhi, Zia Choudhry, Bernie Sattin, Wim Noel, Charlotte Gary, Mazen M. Dimachkie
Refining the Conceptual Model of Patient Experiences in Chronic Inflammatory Demyelinating Polyneuropathy: Integrating New Data and Perspectives
Kayla Scippa, Jake Macey, Alberto E. Batista, Janice Wong, Elizabeth Collins, Hannah Edge, Lisa Ford, Sarah Knight, Sheryl Pease
Safety And Efficacy Results of Nipocalimab in Adolescents with Generalized Myasthenia Gravis During Active-Treatment and Long-term Extension Phases: VIBRANCE-MG Phase 2/3 Study
Jonathan Strober, Shawn Black, Marie Fitzgibbon, Saunder Bernes, Akiyuki Uzawa, Yasuhiro Kimoto, Keiko Ishigaki, Tuan Vu, Erin E. Neil Knierbein, Hideki Shimomura, Erik H. Niks, Dan Huang, Yaowei Zhu, Sindhu Ramchandren
Safety Profile of Nipocalimab, a New Neonatal Fragment Crystallizable Receptor Blocker in the Phase 3 VIVACITY Study
Hans Katzberg, Maria Ait-Tihyaty, Ibrahim Turkoz, Kavita Gandhi, Sindhu Ramchandren
Symptom Severity Assessment Using Quantitative Myasthenia Gravis Items and Domains in a 24-week, Phase 3 Study (Vivacity-MG3) of Nipocalimab in Generalized Myasthenia Gravis
Mazen M. Dimachkie, Constantine Farmakidis, Kavita Gandhi, Maria Ait-Tihyaty, Ibrahim Turkoz, Sheryl Pease, Zia Choudhry, Charlotte Gary, Antoine C. El Khoury, Sindhu Ramchandren
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
